Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Orphazyme

Nature Biotechnology volume 31, page 189 (2013)Cite this article

Subjects

A Corrigendum to this article was published on 10 June 2013

This article has been updated

This Danish startup intends to use a chaperone protein to treat lysosomal storage disorders.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 04 June 2013

    In the version of this article initially published, Steven Walkley's name was misspelled as Steven Walkely. The error has been corrected in the HTML and PDF versions of the article.

Author information

Authors and Affiliations

  1. Ann Arbor, Michigan

    Ken Garber

Authors
  1. Ken Garber
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garber, K. Orphazyme. Nat Biotechnol 31, 189 (2013). https://doi.org/10.1038/nbt0313-189

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0313-189

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing